Sign in

Jonathan Zhang

@jzhangecon.bsky.social
72 followers 57 following 16 posts

Assistant Professor, Duke Sanford www.jonathanzhang.net

PostsRepliesMedia
Reposted by Jonathan Zhang
NBER @nber.org · 18/08/2026
The 988 calling code improved suicide crisis line call answering in states with larger pre-launch capacity gaps, but gains were not accompanied by lower suicide mortality, from Benjamin Hansen, Niketana Kannan, and @jzhangecon.bsky.social www.nber.org/papers/w35601
054
Reposted by Jonathan Zhang
Catherine Rampell @crampell.bsky.social · 22/07/2026
In Danish data, GLP-1 treatment reduces long-term sickness leave by 17.3%. Estimated total fiscal benefits of GLP-1 initiation are approximately 1.3–1.5% of annual labor income per employed individual. www.nber.org/papers/w35475
nber.org
The Labor Market Impacts of GLP-1s
Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, an...
625260
Reposted by Jonathan Zhang
NBER @nber.org · 21/07/2026
GLP-1 treatment cuts long-term sickness leave by 17 percent in Danish admin data, with fiscal benefits of 1.3–1.5 percent of annual earnings, but no impacts on income or employment, from Daysal, Fredrickson, Kristiansen, Trandafir, and @jzhangecon.bsky.social www.nber.org/papers/w35475
0123
Jonathan Zhang @jzhangecon.bsky.social · 01/04/2026
@nber.org digest today summarizing our GLP-1 work: www.nber.org/digest/20260...
nber.org
The Health and Healthcare Spending Effects of GLP-1s
020
Jonathan Zhang @jzhangecon.bsky.social · 11/03/2026
Check out our new work on in utero exposure to opioids!
000
Reposted by Jonathan Zhang
NBER @nber.org · 15/01/2026
Examining GLP-1s usage using data on 1.4M diabetic or obese veterans finds that PCP adoption drives large metabolic improvements matching trials—but no short-run cuts to emergency department use or medical spending, from Bock, Moshfegh, and @jzhangecon.bsky.social www.nber.org/papers/w34667
041
Reposted by Jonathan Zhang
John Holbein @johnholbein1.bsky.social · 12/01/2026
Two new preprints on the efx of GLP-1s just dropped. They use different samples, data, & designs. But they come to the same conclusion on one point: GLP-1s do not generate meaningful short- to medium-run reductions in non-GLP-1 medical spending, despite clear health benefits.
2238
Jonathan Zhang @jzhangecon.bsky.social · 12/01/2026
🚨Do GLP-1s “pay for themselves”? We study real-world impacts at scale. An estimated 1 in 8 Americans have tried GLP-1s. But beyond clinical trials, we know surprisingly little about their real-world effects. Paper: nber.org/papers/w34667 (w/ @jasminmoshfegh.bsky.social & Sam Bock) 🧵1/10
nber.org
Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence From Provider Adoption
Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, an...
142
Jonathan Zhang @jzhangecon.bsky.social · 29/08/2025
We examine how bias in a widely used medical device against individuals with darker skin tones propagates into disparities in subsequent medical treatment
010